Axelrod Research — NU: A Higher Price Still Lacks the Credit Proof
Nu's payments-to-banking thesis remains plausible, but the evidence still does not establish that credit economics justify paying more for it. With the shares now above the level in the original review and no new qualifying research in today's Swarm window, the decision is HOLD, not chase.
NU — Nu Holdings
The call: HOLD.
Why now. The 26 August review recorded NU at $15.13 as of 2026-08-26 and judged the central claim only partly verified: payments may support broader banking monetization, but the underlying article supplied no NU-specific take-rate, credit-quality or profitability proof. NU closed at $15.68 on 2026-09-03, up 3.6% from that review price, while today's research window added no company evidence that closes those gaps. [1][2]
What the thesis was—and what changed. The live thesis is that NU's digital bank across Brazil, Mexico and Colombia can use payments as the interface and earn the economics through interest and fee income. The review also identified the variables that can break that bridge: credit quality, funding, regulation, foreign exchange and execution. What changed is price, not underwriting: $15.13 on 2026-08-26 became $15.68 on 2026-09-03; the evidentiary rating remains “partly verified.” [1][2][3]
Evidence. The source article's broad contention was that Latin American payment fees approach zero and economics migrate to credit and banking. Our 26 August analysis found NU's model consistent with that adjacency, but found no company-specific take-rate, normalized-margin, credit-quality or reconciled cash-flow evidence in the article. That is the decisive omission because NU is a lender as well as a payments platform; volume alone cannot establish durable shareholder returns. [1][3][4]
Levels & triggers. Do not add solely because the shares are below their $18.98 52-week high as of 2026-08-26; that range is context, not valuation. Upgrade to ACCUMULATE only after a primary filing supplies a consistent valuation framework alongside stable credit quality, funding resilience and profitable monetization across reporting periods. Downgrade to AVOID if the next filing shows weakening credit quality or funding pressure without offsetting risk-adjusted returns. [1][3][4]
Horizon. This HOLD is valid through the next reported results and filing cycle, when those credit, funding and profitability tests can be rerun on primary data. [3][4]
The bear case to this HOLD. NU may already have enough operating leverage and cross-sell strength that waiting for fully reconciled proof means missing further upside. That is a real opportunity cost—but the original evidence did not quantify those economics, and a $73.5bn market capitalization as of 2026-08-26 leaves little room for a thesis built mainly on adjacency. [1][3]
What I'm watching: the next results package for credit-quality, funding and normalized-profitability disclosures that can turn the payments-to-banking narrative into an underwritten return case. [3][4]
Sources
Independent equity analysis, for information only, not investment advice.